+

WO2003037372A1 - Procede de retablissement de processus physiologiques perturbes et medicament - Google Patents

Procede de retablissement de processus physiologiques perturbes et medicament Download PDF

Info

Publication number
WO2003037372A1
WO2003037372A1 PCT/RU2002/000377 RU0200377W WO03037372A1 WO 2003037372 A1 WO2003037372 A1 WO 2003037372A1 RU 0200377 W RU0200377 W RU 0200377W WO 03037372 A1 WO03037372 A1 WO 03037372A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
items
medicinal product
days
patient
Prior art date
Application number
PCT/RU2002/000377
Other languages
English (en)
Russian (ru)
Inventor
Oleg Iliich Epshtein
Tamara Mikhailovna Kolyadko
Mark Borisovich Shtark
Original Assignee
Oleg Iliich Epshtein
Tamara Mikhailovna Kolyadko
Mark Borisovich Shtark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2001129325/14A external-priority patent/RU2001129325A/ru
Application filed by Oleg Iliich Epshtein, Tamara Mikhailovna Kolyadko, Mark Borisovich Shtark filed Critical Oleg Iliich Epshtein
Publication of WO2003037372A1 publication Critical patent/WO2003037372A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Definitions

  • Iz ⁇ b ⁇ e ⁇ enie ⁇ n ⁇ si ⁇ sya ⁇ ⁇ blas ⁇ i medicine and m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ to treat ⁇ a ⁇ l ⁇ giches ⁇ i ⁇ Sind ⁇ m ⁇ v, ⁇ busl ⁇ vlenny ⁇ or s ⁇ v ⁇ zhdayuschi ⁇ sya na ⁇ usheniem ⁇ egulyatsii ⁇ lyuchevy ⁇ ⁇ izi ⁇ l ⁇ giches ⁇ i ⁇ ⁇ tsess ⁇ v - mezh ⁇ le ⁇ chny ⁇ vzaim ⁇ deys ⁇ vy, ⁇ li ⁇ e ⁇ atsii and di ⁇ e ⁇ entsi ⁇ v ⁇ i ⁇ le ⁇ .
  • the invention is aimed at improving the efficacy and safety of treating diseases caused by the violation of physiological processes
  • SIGNIFICANT FOX (DR. 26) 2 ⁇ eguli ⁇ uemy ⁇ tsi ⁇ inami and ⁇ un ⁇ tsi ⁇ naln ⁇ ⁇ d ⁇ bnymi them bel ⁇ ami and ⁇ e ⁇ idami, ⁇ e v ⁇ lyuchal ⁇ would not ⁇ davlenie (bl ⁇ i ⁇ vanie) and m ⁇ di ⁇ i ⁇ atsiyu bi ⁇ l ⁇ giches ⁇ y a ⁇ ivn ⁇ s ⁇ i tsi ⁇ in ⁇ v or ⁇ un ⁇ tsi ⁇ naln ⁇ ⁇ d ⁇ bny ⁇ them ⁇ egulya ⁇ v u ⁇ azanny ⁇ ⁇ tsess ⁇ v;
  • the invention is also directed to the creation of a new medicinal product that does not have any expressed effect.
  • the medicinal product has an active form of overdose which is very small or small, immune or natural, or is immune to health or is immune.
  • an active form of an antibody for a single or a small amount of an antifreeze or a mixture of an amount of at least
  • the medicinal product is prepared by the following method.
  • cytokines By biological methods, these cytokines, squirrels, or peptides are consumed and one or several of them are selected.
  • ⁇ further ⁇ azhdy izb ⁇ anny bel ⁇ , ⁇ e ⁇ id or eg ⁇ ⁇ agmen ⁇ (at least 3 amin ⁇ isl ⁇ nzh ⁇ s ⁇ a ⁇ v) is ⁇ lzuyu ⁇ in ⁇ aches ⁇ ve immun ⁇ gena for immunization lab ⁇ a ⁇ nzh zhiv ⁇ ny ⁇ and ⁇ lucheniya ⁇ li ⁇ l ⁇ nalnzh immunnzh an ⁇ i ⁇ el, or gib ⁇ id ⁇ mn ⁇ y ⁇ e ⁇ n ⁇ l ⁇ gii for ⁇ lucheniya m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el. Obtained antibodies are cleared by the method of an affirmative process.
  • the current processing in the process of deducing the concentration is also possible to carry out ultrasound, electric or other physical interference.
  • Example 2 Patient U., 34 years old, for 10 years, it suffers from a mild moderate course, complicated by an arrhythmic arthritis.
  • the symptoms of the disease are assigned to: a generic antibody for the patient 10 - in the case of a dilution of 2 patients.
  • the manifestation of new plaques was improved, the general condition improved, the symptoms of arthritis disappeared; after 10 days after the start of treatment - an apparent regression of all the general plaques, the remission of the disease is reached. It is recommended that you take a drug.
  • Example Z When an experimental study of the efficacy of overdose of interleukin 13 (IL-13) was performed, an analgesic increase was sensitized (sensitized). For this test, with a weight of 300 g, they were sensitized by the intramuscular injection of 0.5 ml of a physiological solution containing valbumin in a dose of 20 mg and 100 mg of aluminum hydroxide. After 3 weeks after sensitization, an anaphylactic reaction ( ⁇ ) was caused by a discontinuing dose of valbumin, which was administered as an aerosol within 60 minutes (0.5% in 0.9%).
  • IL-13 interleukin 13
  • the large cross-border antibodies for the IL-13 group (a mixture of the C12 + C30 + C200 homogeneous dilutions) were administered at a daily interval of 0.5 ml.
  • the on-site group entered the distilled water.
  • Example 4 The ability to over-tighten the body of an antibody to an interleukin 12 (IL-12) stimulates the inactivity by reducing the inconvenience of the decrease
  • Generated tuberculosis was simulated by introducing vascular tissue at a rate of 0.5 in vascular infusion to the male inferior males.
  • On-line antibodies for the IL-12 fragment (a mixture of homogenous dilutions C6, C1000) were injected with a dose of 0.2 ml of an intruder for 2 days. The on-site group entered the distilled water. Treatment was started after infection development (on day 4).
  • EXAMPLE 5 In mice of the C obedient line (18-22g), the systemic condition was simulated by introducing an internal perfusion in a group of 0.1 ml. Further m ⁇ i ⁇ y ⁇ n ⁇ y g ⁇ u ⁇ y ⁇ az 1 to 3 chasa ⁇ luchali ⁇ e ⁇ aln ⁇ ⁇ 0.2 ml m ⁇ n ⁇ l ⁇ nalny ⁇ an ⁇ i ⁇ el in ⁇ e ⁇ ley ⁇ inu ⁇ 1 and ⁇ ⁇ li ⁇ l ⁇ nalny ⁇ an ⁇ i ⁇ el ⁇ a ⁇ u ne ⁇ za ⁇ u ⁇ li al ⁇ a, ⁇ azhdy an ⁇ i ⁇ el view - in a mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C6 + C30 + C200. Our business team received distilled water. When evaluating the survival rate, it was found that in the experimental group the lethality was 36% ”, having only 100% in the economy; The death of livestock occurred
  • Example 6 Patient L., 49 years old, complained of increased fatigue, fatigue, pain and decreased mobility. Diagnosis: "A simple two-sided distress.” Designated by the industrial division of the Mono-National Antibody 1 in the home breeding C50 ⁇ 10
  • SIGNIFICANT FOX (DR. 26) 8 drops per ⁇ 3 or 3 times per day. After a week, physical activity and pain relief were noted.
  • Example 7 Patient,., 56 years old, had been treated for non-operative inoculations with complaints of cough, increased pain. An investigation revealed an increase in body temperature up to 37.5 ° ⁇ .
  • ⁇ aznachenie ⁇ entsi ⁇ vann ⁇ g ⁇ ⁇ as ⁇ v ⁇ a m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el ⁇ an ⁇ ag ⁇ nis ⁇ u ⁇ etse ⁇ a in ⁇ e ⁇ ley ⁇ ina 1 g ⁇ me ⁇ a ⁇ iches ⁇ m ⁇ azvedenii C50 ⁇ 15 ⁇ a ⁇ el 3 ⁇ aza day ⁇ zv ⁇ lil ⁇ n ⁇ maliz ⁇ va ⁇ ⁇ em ⁇ e ⁇ a ⁇ u ⁇ u and us ⁇ ani ⁇ ⁇ ashel che ⁇ ez ⁇ sle 4 days of treatment.
  • EXAMPLE 8 Overhead lines of C57 line were injected with 0.1 ml of a complex of antibodies to intuleukin 2 in the home breeding of C ⁇ . The separation of the indicators of the immune system after 7 days of the introduction of the drug revealed an increase in the stimulation of stimulation by 30%.
  • Example 9 Patient Sh., 48 years old, treated with complaints of heartbeat, weakness, asthma. An examination revealed iron deficiency anemia, a decrease in the level of hemoglobin up to 70 g / l. Diet and food was assigned to a multi-functional antibody for Interaleukin 3 in a home breeding of C200 1 teaspoon 3 times a day. After 2 weeks of regression, the stated complaints were ascertained, the level of hemoglobin increased to 110 g / l.
  • SIGNIFICANT FOX 9 Acceptance of endothelial cells of expression of ⁇ -1 adhesion molecules by 20% after 48 hours of incubation.
  • Example 11 Patient ⁇ ., 7 years old, was consulted in connection with complaints of sickness, absenteeism, pain, and illness. The investigation revealed eosinophilia caused by ascaridosis.
  • ⁇ aznachenie ⁇ vechi ⁇ ⁇ li ⁇ l ⁇ nalny ⁇ an ⁇ i ⁇ el ⁇ in ⁇ e ⁇ ley ⁇ inu 5 in admixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C12 + C30 + C200 ⁇ 1 chayn ⁇ y l ⁇ zh ⁇ e 3 ⁇ aza day ⁇ zv ⁇ lil ⁇ us ⁇ ani ⁇ u ⁇ azannye zhal ⁇ by che ⁇ ez 4 days treatment 10 days treatment che ⁇ ez ⁇ d ⁇ ve ⁇ zhden ⁇ ⁇ su ⁇ s ⁇ vie gelmin ⁇ za and e ⁇ zin ⁇ ilii.
  • Example 12 Patient D., 65 years old, treated with complaints of pain in the back. In the course of the investigation, an outbreak of an obstructive lumbar obstruction was revealed. Potentially distributed equipment is assigned to the intaleukin 6 in a home dilution of C200 200 1 tablet 3 times a day. After 5 days of the onset of disease, the elimination of the pain syndrome is detected.
  • EXAMPLE 14 An experiment has been made to evaluate the effect of reducing active antibody intake on intuleukin 8 on the development of inflammation in the living room. For 7 days, a test group received an oral preparation of 0.5 ml of a small-scale anti-IL-8 antibody diluted in a C100 homogenous dilution. Accounting
  • SIGNIFICANT FOX (DR. 26) 10 differences in the mass of extremities in the commercial and experimental groups revealed a 2–7-day decrease in the total reaction by the action of the drug by 35%.
  • Example 15 Patient C, 36 years old, was treated with pallinosis. It is designated as an integral mono-antibody for intereleukin 9 in the form of a solution in the Homophilic dilution C50 ⁇ 5 5, the droplet is intranasal 2 times a day. After 5 days of illness, the symptoms of allergies are eliminated.
  • Example 16 Patient ⁇ ., 58 years old, suffering from ischemic heart disease, was treated with complaints of pain in the area of the heart and insufficient stress. It is offered by a multi-ethnic antibody for 10 diluted home-breeding C ⁇ , for 1 table 3 times a day. After 3 days, the patient noted a decrease in the severity of the pain syndrome. Recommend a cure for treatment.
  • Example 17 Patient D., 64 years old, treated with complaints of pain, cyanosis, and low-grade infrequency. In the course of the examination, a diagnosis of a deep vein of burning was diagnosed on the basis of an increase in the content of the heart in the front. It is recommended for use with antibodies to interleukin 11 in a mixture of Homophilus dilutions ⁇ b + Sz ⁇ + Syu ⁇ 1 teaspoon 3 times a day. After 7 days, it was found that the complaint was fixed, the number of cases was normalized.
  • Example 18 For children with small-breast cancer, induced by benzene, they injected 0.5 ml of an intensive-care drug in the Republic of Belarus. It has been established that the 30-day introduction of the drug reduces the size and quantity of pulses by 40%, increases the life span of life, and also increases
  • SIGNIFICANT FOX (DR. 26) 11 practical activity with a cell, which is at the core of an experimental group.
  • mice of the C57 ⁇ line were installed, that the introduction of an external injury prevents a person from suffering from thrombocytopenia.
  • Conditions of administration at a dose of 0.1 ml in a diluted C200 dilution daily for 7 days.
  • Example 23 The incubation of fractions of the skin of a human being is 0.5% of the share of the investment in the inlet of the inlet of the 120-year-old inlet
  • Example 26 A person who was affected by an alter- native virus caused an increase in the level of internal disturbance in a case of incidence of miscarriage of interest.
  • Example 27 Patient ⁇ ., 56 years old, treated with complaints of painful rash on the lips and other faces, resulting in a burning pain and an increase in temperature. Diagnosed with herpes infection and recommended
  • Example 28 Patient U., 24 years of age, being at the 7th month of pregnancy, is socialized due to a late pregnancy. Designation
  • SIGNIFICANT FOX 13 ⁇ entsi ⁇ vann ⁇ g ⁇ ⁇ as ⁇ v ⁇ a m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el an ⁇ i ⁇ el ⁇ -in ⁇ e ⁇ e ⁇ nu ⁇ au (G ⁇ - ⁇ ai) in g ⁇ me ⁇ a ⁇ iches ⁇ m ⁇ azvedenii C200 ⁇ zv ⁇ lil ⁇ us ⁇ ani ⁇ ⁇ e ⁇ i, and gi ⁇ e ⁇ enziyu ⁇ izna ⁇ i ⁇ e ⁇ - ⁇ latsen ⁇ a ⁇ n ⁇ y ned ⁇ s ⁇ a ⁇ chn ⁇ s ⁇ i che ⁇ ez 7 days ⁇ iema ⁇ 10 ⁇ a ⁇ el 3 ⁇ aza per day.
  • mice with antibodies to ⁇ caused a substantial (2.3-fold) decrease in the number of metastatic nodes in the lungs, and the inhibition rate of metastasis was 73%.
  • Example 30 Patient ⁇ ., 58 years old, treated with complaints of pain in his lower joints, and their breathing and decreased mobility. As a result of the investigation, a diagnosis of “reactive arthritis” was made. The designation of the unit is mono-local
  • EXAMPLE 32 Patient ⁇ ., 28 years old, received a cure for treatment of a newly acquired immunodeficiency syndrome, which is present in the presence of a sarcoma disease.
  • ⁇ aznachenie ⁇ e ⁇ a ⁇ a ⁇ a m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el ⁇ ley ⁇ zingibi ⁇ uyuschemu ⁇ a ⁇ u (LI ⁇ ) in a mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C12 + C200 + SYU00 ⁇ 1 ⁇ able ⁇ e 3 ⁇ aza day vyzval ⁇ ⁇ eg ⁇ ess ⁇ u ⁇ li, uluchshil ⁇ ⁇ bschee sam ⁇ chuvs ⁇ vie ⁇ atsien ⁇ a che ⁇ ez ⁇ sle 14 days of treatment.
  • Example 33 Patient ⁇ ., 30 years old, was discharged to the department of hematology with a diagnosis of autoimmune agranulocytosis, the content of leukemia in the patient on 9 October.
  • Example 34 Patient L., 67 years old, treated with complaints of easy healing and expulsion in the area of second-degree burns,
  • SIGNIFICANT FOX (DR. 26) 15 cases in 2 weeks prior to visit. Designated by the manufacturer of antibodies ⁇ ⁇ - ⁇
  • P ⁇ ime ⁇ 35 is ⁇ lz ⁇ vaniem e ⁇ s ⁇ e ⁇ imen ⁇ aln ⁇ y m ⁇ deli se ⁇ iches ⁇ g ⁇ v ⁇ s ⁇ aleniya at ⁇ ys, vyzvann ⁇ g ⁇ ⁇ d ⁇ zhnym introduction ⁇ ul ⁇ u ⁇ y ⁇ aigeiz ( ⁇ YU 90) ⁇ azan ⁇ presence bi ⁇ l ⁇ giches ⁇ y a ⁇ ivn ⁇ s ⁇ i at sve ⁇ malzh d ⁇ z an ⁇ i ⁇ el ⁇ T- ⁇ S ⁇ (g ⁇ anul ⁇ tsi ⁇ a ⁇ ny ⁇ l ⁇ nies ⁇ imuli ⁇ uyuschy ⁇ a ⁇ ).
  • Antibodies in the Homo dilution SJ00 introduced a direct dose of 0.3 ml for 5 days. ⁇ The experimental group of livelihoods showed a marked decrease in lethality (by 3 times), a significant decrease in mute-septic phenomena in the incidence of increased incidence of physical and physical activity.
  • SIGNIFICANT FOX (DR. 26) 16 mkg / kg.
  • ⁇ ysy ⁇ y ⁇ n ⁇ y g ⁇ u ⁇ y ⁇ sle administration tse ⁇ ulina ⁇ luchali a ⁇ ivi ⁇ vannye sve ⁇ malye d ⁇ zy ⁇ li ⁇ l ⁇ nalysh ⁇ ⁇ lichi ⁇ an ⁇ i ⁇ el ⁇ ⁇ em ⁇ inu S ⁇ S (su ⁇ k ⁇ e- ⁇ ise ⁇ ⁇ eigg ⁇ Y ⁇ set ⁇ a ⁇ gas ⁇ a ⁇ ) (an ⁇ i-S ⁇ S) - mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny C12 SZ ⁇ , C200 - in v ⁇ dn ⁇ m ⁇ as ⁇ v ⁇ e as sv ⁇ b ⁇ dn ⁇ g ⁇ d ⁇ s ⁇ u ⁇ a in ⁇ e ⁇ vye su ⁇ i and then at 0.2 ml 1 time per day.
  • the kruppy kruppy krysys received the distilled water.
  • the severity of ⁇ P was assessed, separating the level of plasma amylase and moderate changes in the pancreas (the degree of failure of the acinus cells, the degree of intensity was intense).
  • the severity of the VAS was determined by measuring the incidence of mycosis of the lungs and the activity of myelopexydase.
  • ⁇ yyavlen ⁇ , ch ⁇ at ⁇ ys, ⁇ luchavshi ⁇ an ⁇ i ⁇ ela ⁇ S ⁇ S, che ⁇ ez 1 su ⁇ i ⁇ sle administration tse ⁇ ulina d ⁇ s ⁇ ve ⁇ n ⁇ below were u ⁇ ven amylase syv ⁇ i (1.8 ⁇ aza) s ⁇ e ⁇ en ne ⁇ za ⁇ le ⁇ atsinus ⁇ v (3 ⁇ aza) s ⁇ e ⁇ en ⁇ e ⁇ a ⁇ a ⁇ en ⁇ imy (2.3 ⁇ aza) vy ⁇ azhenn ⁇ s ⁇ v ⁇ s ⁇ ali ⁇ eln ⁇ y pancreatic fluid infiltration (2.5 times) than in the control.
  • the introduction of the drug also led to a decrease in the activity of myeloepoxidase (by 1.8 times) and a decrease in the incidence of lung vessels (by 3 times).
  • Example 38 Patient ⁇ ., 22 years old, was treated by a doctor with severe allergic disease (food allergy), a standard treatment. Appointed: mono-local antibodies to ectaxinum - a mixture of homogeneous dilutions ⁇ 12 + ⁇ 30 + ⁇ , only 1 tablet 2 times a day. On the 3rd day of treatment, the patient noticed a significant reduction in skin pruritus, normalization of sleep; After 7 days after the start of treatment, skin rash and itching were completely regressed. It is recommended that you take a drug. History of 6 months: recurrence of dermatitis was not great, despite non-compliance with strict children.
  • Example 40 Patient ⁇ ., 45 years old, treated with complaints of minor vesicular rashes and itching of the skin after an insult. Diagnosed with ⁇ papivnitsa. It is assigned a mnogonalnyh antibodies ⁇ ⁇ (a single chemically active factor) in a mixture of homogenous dilutions of C6 + C30 + C200 for 1 day. After 2 ⁇ days of illness, itching and hematomas were noted.
  • Example 41 Patient ⁇ ., 43 ⁇ years old, had complained of numerous complaints in the ambulatory region. It is designated as a pre-empted food solution for an antibody with a diluted dilution of C30 at 1 tea day on a 3-day basis. After 3 days after the start of treatment, a registered decrease in the number and size of the facilities has been registered.
  • Example 42 Patient ⁇ ., 48 years old, was treated by a patient for obstructive lumbar obstruction. ⁇ aznachen ⁇ e ⁇ alny ⁇ iem m ⁇ n ⁇ l ⁇ nalnzh an ⁇ i ⁇ el ⁇ ⁇ em ⁇ inu (Zh ⁇ in g ⁇ me ⁇ a ⁇ iches ⁇ m ⁇ azvedenii C200 ( ⁇ luchenn ⁇ m ⁇ i ⁇ m ⁇ schi ⁇ b ⁇ ab ⁇ i zvu ⁇ vym gene ⁇ a ⁇ m ⁇ i 20 Hz), ⁇ 5 ⁇ a ⁇ el 3 ⁇ aza per day. Che ⁇ ez 3 days of starting treatment ⁇ sle za ⁇ egis ⁇ i ⁇ van ⁇ us ⁇ anenie b ⁇ lev ⁇ g ⁇ Sind ⁇ ma.
  • Example 43 Patient ⁇ ., 32 radia, was treated with complaints of pain in the lower abdomen and an increase in body temperature that had occurred after cooling. ⁇
  • SIGNIFICANT FOX (DR. 26) 18 history of adnexitis, an unhealthy process in the external area. It is designated for industrial use of mono-analgesic antibodies ⁇ -c- ⁇ -c- ⁇ -chemokine C ⁇ in a homogeneous dilution of C6 ⁇ 10 kapel at a rate of 5 times a day. After 3 days of the onset of regression, the elimination of the pain syndrome and normalization of the body temperature.
  • Example 45 Patient L., 15 years old, handled complaints of dry, itchy rashes in the area of ankle bending and neck. According to the results of the investigation, a diagnosis of “neurology” was made. It is designated as a simple overdose to a multiple of antibodies to a pediatric dilution of C200 dilution of 1 table 2 times in a day. After 5 days of treatment, the itching and skin problems were registered.
  • Example 46 Patient G., 28 years old, treated with complaints of persistent pain in the lower jaw, which increased after cooling, and increased temperature. In the course of the investigation, the diagnosis was diagnosed: neuralgia is traditional. The appointment of a small-scale antibody to the Khemokin ⁇ fie-1 in a homogeneous dilution of ⁇ 50 takes 1 time 3 times a day, eliminates the need to take the test off.
  • Example 47 Cells of mice of the C57 ⁇ line were incubated with 0.1% of a small-scale antibody for ⁇ -chemotherapeutic dilution of ⁇ . When adding an intubation with antibodies ⁇ carlets for melanoma cells ⁇ 16 (at a rate of 10: 1), it was found that it was inconvenient
  • Example 48 ⁇ The experiment on the rifle with an overexposure (Eruli's test) is shown to protect the patient from an anomalous rate. ⁇ A group of lively animals who had received a direct oral administration of a potential antibody in the homosexual dilution of SJU 0.1 ml per 30 days experienced a 30% increase in life.
  • Example 49 Patient L., 31 years old, was treated with migraine, a resistant treatment for conventional treatment.
  • the drug is recommended for use with a comorbid-activating agent (a mixture of H20 dilutions C12 + C30 + C200), 1 tablet daily.
  • a comorbid-activating agent a mixture of H20 dilutions C12 + C30 + C200
  • 1 tablet daily for 3 weeks of the onset of the drug, there was no registered migraine. Recommend a cure for treatment.
  • Example 50 Patient ⁇ ., 47 years old, dealt with complaints of mild headaches and heaviness in the heart. In the course of the investigation, an increase in arterial pressure up to 160/90 mm was detected. Diagnosed with a chronic illness of 2 degrees. It is proposed to use a potentiated antibody for Chemokine 5 ⁇ in a home dilution of C200 10 10 drops 3 times a day and daily measurement ⁇ D. After 2 weeks, a stable normalization of the arterial pressure is noted.
  • Example 52 The experiment simulated an autoimmune panic in mice of the C57 ⁇ 1 line, for which the mice were given an internal interval with an interval of 1 hour / week.
  • the on-line group received the distilled water.
  • the pancreatic test index (GCF) was calculated as the ratio of gland weight / mouse weight;
  • GCF pancreatic test index
  • SIGNIFICANT FOX 21 degree of failure of the acinus cell, degree of the process of inflammation, the incidence of extensive pancreatic infiltration was lower than in the case of the card.
  • the TITR of the auto-counter in the panel was 1:64, in mice that received the anti- ⁇ -61, - 1: 4.
  • Example 53 A sick man, 46 years old, was allowed to go to a business unit for a scheduled emergency transaction. It has been identified that there is a tendency for patients to have health problems after they have been treated.
  • EXAMPLE 54 Patient C., 27 years old, was treated with a nesting alopecia for the last 3 months. Appointed: active small doses of a small antibody for the transfusion factor of the beta 2 person - a mixture of the dilution, 1 dilution. After a second appearance after 2 weeks: the restoration of the alopecia was stopped, the restoration of the hair began. A month after the start of treatment: there are no signs of alopecia.
  • Example 55 Patient G., 54 years old, treated with complaints of cough, a low-grade temperature treatment during the course of 3 weeks after the transferred group. In the course of the investigation, the presence of a secondary immunodeficiency was established (lymphopenia, decreased immunoglobulins in the serum). It is designated for industrial use of antibodies to the transformed factor of ⁇ in a diluted C200 dilution of 10 drops at a rate of 3 times per day. After 5 days, normalization of the temperature and the elimination of cough were noted; after 10 days, normalization of the indicators was detected.
  • EXAMPLE 56 An experiment in the field of at-risk skin of people is shown to be good, and at-risk patients are at risk of being at risk of having A 0.1% hostile animal in the C30 breeding was introduced into the 96 well plate of the hole containing the cellar. After 24 hours, 3 ⁇ -leucine was added to the cells. The results were taken into account with the inclusion of a radioactive label for 4 hours of incubation. Installed stimulation of the inclusion of the label by the action of the preparation of antibodies by 35%.
  • Example 57 Patient ⁇ ., 59 years old, was treated with compensated insulin-dependent diabetes mellitus. It is proposed for use with antibodies to an insulin-friendly compound (HF) in a diluted C200 dilution of 1 tablet 3 times a day. After 2 days, a decrease in the severity of clinical symptoms of hyperglycemia was registered, after 7 days - a steady normalization of glycemia, an increase in tolerance to physical symptoms.
  • HF insulin-friendly compound
  • Example 58 When studying the effect of active overdose on the basis of antibodies to insulin-like factor 1 (phase 1) on the course of ischemic stroke, there is a slight increase in ischemia
  • SIGNIFICANT FOX (DR. 26) 23 median cerebral artery therapy with general anesthesia.
  • the all-round antibodies to the Fragment 1 type (a mixture of C200 + CU00 dilutions) introduced a daily dose of 0.4 ml per day. during the day, the 2nd group - daily for 30 days.
  • Example 59 Patient L., 54 years of age, was treated with complaints of pain in the lower back and a decrease in the sensitivity of the outbreak of illness. ⁇ history - osteoarthritis, radicular syndrome. The appointment of an antibody combination to the incidence of miscarriage in a homosexual dilution of SJ00 at 1 time of 3 times a day was favorable to an increase in the likelihood of 5 days
  • Example 60 Patient ⁇ ., 48 years old, treated with complaints of increased frequency of onset of bronchial asthma and a decrease in the effectiveness of medical treatment. Assigned to a potential-based multi-channel anti-theft system ⁇
  • SIGNIFICANT FOX 24 factories of breeding in the home breeding C200 at 1 teaspoon 3 times a day. A registered decrease in the intensity and frequency of operations after 3 days of reception.
  • Example 61 Patient ⁇ ., 71 years old, suffering from non-insulin-dependent diabetes mellitus, was treated with complaints of an ulcer in the lower part of the stomach that did not heal for 2 weeks. Diagnosed with a “peptic ulcer”. Assigned to a meal with a potentiated component of an antibody for an epidemic in the city divorce on 10 October. After a week, ulcer healing is registered.
  • Example 62 Patient P., 62 years old, was treated with relapsing two-stage erosion of the disease on the basis of diabetes mellitus type 2. Treatment for 3 months with drugs that stimulate regeneration (salt, actevin, and degeneration) did not produce an expressed effect. Appointment: casualties for epidemiological treatment of a human patient (a mixture of homogeneous dilutions of C30 + C200 + CU00) - 1 treatment is required for 2 patients After the onset of manifestation after 7 days, a decrease in the area of erosion by 2 times was revealed, after 4 weeks after the start of treatment of erosion, the patient was completely epithelized.
  • Example 63 Application to the conjunctiva of the eye at a daily rate of 0.1 ml of a dilution of an antibody for the treatment of worsening of the medication
  • SIGNIFICANT FOX (DR. 26) 25, the ocular fundus is undergoing: an effective retinopathy, a significant number of new vessels, and multiple foci of accidents.
  • Example 65 Patient W., 27 years old, treated with complaints of weakness, headache, nausea, tinnitus. During the investigation, a decrease in the arterial pressure up to 90/60 mm. ⁇ .st. Diagnosed with vegetative-vascular distress. It is designated as a direct access unit for the installation of an industrial unit for industrial use (gas supply unit, gas supply, gas supply, gas supply, gas After 2 days of illness, normalization of arterial pressure and improvement of well-being are registered.
  • an industrial unit for industrial use gas supply unit, gas supply, gas supply, gas supply, gas supply, gas After 2 days of illness, normalization of arterial pressure and improvement of well-being are registered.
  • Example 66 In the experiment, the C57 etti ⁇ line mice introduced an increase in the potential for the incidence of the patient’s neglect of the patient. There was a significant increase in the content of carcass in the large brain (by 20%), as well as in weight and carnus of the thymus by 30%.
  • Example 67 Patient ⁇ ., 57 years old, has a long-term history of deterioration of the chronic ⁇ , has been hospitalized due to the growing liver failure. Appointed: multiple antibodies to the growth factor of a herbal mixture in a mixture of herbal dilutions C12 + C30 + C200 1 tablet 3 times a day. After 5 days after the start of treatment, the general condition improved
  • SIGNIFICANT FOX (DR. 26) 26 patients, the clinical and laboratory parameters of the liver were depleted, the level of bilirubin in the blood decreased.
  • EXAMPLE 68 Patient D., 42 years old, suffering from chronic tonsillitis, was treated due to physical pain in the area, due to the temperature of the body. The designation of a wide range of other antibodies to Interleukin 2 in the home breeding of C200 at 1 table 1 at 3 o'clock has eliminated the neglect of the day.
  • Example 69 The experiment on suspensions of the spleen carcasses of C57 ⁇ 1 is shown, which means that the incubation medium contains 0.2%, which is low sho ⁇ esi ⁇ ag ⁇ se ⁇ Gastog, L ⁇ - ⁇ ) in the C12 home breeding promotes stimulation of the active activity of the sediments by 20% after 24 hours of incubation.
  • Example 70 In the context of incubation of the culture of human skin, an infected virus infection, they contributed 1% of the incidence of the disease. It has been found that the release of the antibody causes a reduction in the performance of the culture system by 30% after 24 hours of incubation.
  • Example 73 Patient 3., 51 years old, suffering from chronic obstruction, was treated for a complaint of a muscular distress, and there was a greater risk of pain. Assigned
  • interleukin 1 ⁇ in addition to the commercial mono-antibody, it is suitable for interleukin 1 ⁇ in a diluted dilution of C300 ⁇ 10 droplet 2 times a day. After 2 days after the start of treatment, it was noted that pain and dysuria were relieved.
  • Example 74 Patient ⁇ ., 25 years old, treated with complaints of headaches, cough, elevated temperature. An examination revealed a hypothermia of 38 ° C.
  • Example 75 Patient ⁇ ., 46 years old, suffering from a peptic ulcer of a twelve-year old bowel, complicated complications of the patient, and has had an increase in obesity Served with a small portion of a poultry in a homosexual dilution of a bambesin in a home-grown dilution of C200 for 1 meal in 30 minutes before eating. After 3 days, it is noted that these symptoms have been removed.
  • Example 78 Patient ⁇ ., 11 years old, was advised on a daily basis for enuresis. There is a separate meal for a vasopressin in a homosexual dilution of C200 for 1 night test. For 3 weeks of observation, the incontinence is not detected.
  • Example 79 Patient S., 54 years old, suffering from a disease, was treated by the treatment of the disease. The preparation was assigned a small antibody for an epidemic inhibitor ( ⁇ ) in a dilution of C200 for 3 days. After 3 days, the accessory was bought, after 7, it was completely calculated that there were no other plaques.
  • ⁇ epidemic inhibitor
  • Example 80 Patient L., 34 years old, was treated with complaints of itching in the nose, reading, and fluid sore throat. Diagnosed with vasomotory rhinitis. It is recommended for use with a dilution of antibodies to a bradikinin in a home breeding of C30 at 1 tablet 3 times a day. After 2 days, the symptoms of vasomotor rhinitis have been removed.
  • Example 81 Patient ⁇ ., 34 ⁇ years old, treated with complaints of weakness, headache, fainting, taste distortion. ⁇ a history of 3 wares, royalties. An examination revealed a decrease in hemoglobin up to 80 g / l. The assignment of a small antibody to an eritrophotetin in a home breeding of C24 at 1 teaspoonful of meals resulted in an increase of 3 days per day, which increased the time of the day. After 20 days after the start of treatment, the level of hemoglobin increased to 120 g / l.
  • Example 82 Patient ⁇ ., 54 ⁇ years old, had complained of multiple abnormalities. In the course of the investigation, a thrombosis was detected. Designated with a rimpie of mono-mono-antibodies in the form of a diluted C200 dilution of 1 tablet 3 times a day. After 7 days of recurrence, hematomas were detected.
  • Example 84 Bologna U., 6 years old, at the age of 2 years revealed myasthenia gravis. At the time of treatment, expressed lack of motor skills, generalized muscular weakness, moderate eyelids. Antibodies ⁇
  • SIGNIFICANT FOX (DR. 26) 30 acetyl chronic drugs.
  • mini-antibodies to the ⁇ 40 molecule ligand in the C1000 diluted dilution, only 1 daily test.
  • After 2 weeks after the start of treatment noted the increase in muscle strength, the absence of the disease.
  • After 2 months after the start of treatment a decrease in antibodies was detected in antibodies to acetylcholine receptors, restoration of muscle strength, and development of motor skills. Recommend that you do so.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne un procédé de rétablissement de processus physiologiques perturbés, régulés par des cytokines et par des protéines et des peptides fonctionnellement semblables auxdites cytokines, lequel procédé consiste à introduire une forme activée de doses infimes d'anticorps dirigés contre les cytokines et les molécules fonctionnellement semblables auxdites cytokines dans un organisme, laquelle forme activée est préparée à l'aide d'une dissolution successive répétée et d'une action externe, de préférence selon une technique homéopathique. Le médicament de la présente invention renferme une forme activée de doses infimes d'anticorps monoclonaux ou polyclonaux, immuns ou naturels dirigés contre les cytokines ou des protéines et peptides fonctionnellement semblables auxdites cytokines, laquelle forme activée est préparée à l'aide d'une dissolution successive répétée et d'une action externe, de préférence selon une technique homéopathique. Pour produire les anticorps, on utilise des cytokines solubles ou liées à une membrane cellulaire ou des protéines et des peptides fonctionnellement semblables auxdites cytokines (ainsi que leurs fragments, dont la dimension est égale ou supérieure à trois résidus acides aminés), de préférence d'origine humaine.
PCT/RU2002/000377 2001-10-31 2002-08-06 Procede de retablissement de processus physiologiques perturbes et medicament WO2003037372A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001129325/14A RU2001129325A (ru) 2001-10-31 Способ восстановления нарушенных физиологических процессов и лекарственное средство
RU2001129325 2001-10-31

Publications (1)

Publication Number Publication Date
WO2003037372A1 true WO2003037372A1 (fr) 2003-05-08

Family

ID=20254049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000377 WO2003037372A1 (fr) 2001-10-31 2002-08-06 Procede de retablissement de processus physiologiques perturbes et medicament

Country Status (1)

Country Link
WO (1) WO2003037372A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US7923009B2 (en) 2002-08-02 2011-04-12 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU98109384A (ru) * 1998-05-22 2000-03-10 О.В. Чернова Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2187334C2 (ru) * 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU98109384A (ru) * 1998-05-22 2000-03-10 О.В. Чернова Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EPCHTEII O.I. ET AL.: "Vlianie gomeopaticheskikh doz antitel k antigenou S-100 na elektricheskie kharakteristiki neironalhykh membran", BIOULLETEN EKSPERTIMENTALNOI BIOLOGII I MEDITSINY, no. 4, 1999, pages 466 - 467 *
KELER G., GOMEOPATIA M., MEDITSINA, 2000, pages 35 - 40 *
NASONOV E.L.: "Faktor nekroza opoukholi-a-novaya mishen dlia protivovospalitelnoi terapii revmatoidnovo artrita", ROUSSKII MEDITSINSKII JOURNAL, vol. 8, no. 17, 2000, Retrieved from the Internet <URL:www.rmi.ru/rmj/t8/n17/718.thm> *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871203B2 (en) 2000-06-20 2014-10-28 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8894995B2 (en) 2000-06-20 2014-11-25 Oleg Iliich Epshtein Method of treating a disorder or condition of viral etiology
US9200081B2 (en) 2000-06-20 2015-12-01 Oleg Iliich Epshtein Method for administering homeopathically potentiated antibodies against mediator of inflammation
US9228024B2 (en) 2000-06-20 2016-01-05 Oleg Iliich Epshtein Method of treating hypertension disorder and a pharmaceutical agent
US9303090B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US9303091B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating disorders of the cardiovascular system and a pharmaceutical agent
US9382332B2 (en) 2000-06-20 2016-07-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US7923009B2 (en) 2002-08-02 2011-04-12 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
US8815245B2 (en) 2002-08-02 2014-08-26 Oleg I. Epshtein Method of treating viral diseases
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Similar Documents

Publication Publication Date Title
WO2003055519A1 (fr) Agent pharmaceutique et methode de traitement de maladies s&#39;accompagnant de troubles du tonus vasculaire
WO2001097842A1 (fr) Procede de traitement d&#39;un syndrome pathologique et produit medicamenteux
US4521405A (en) Methods and materials for treatment of disease states involving immunological factors
WO2005000350A1 (fr) Medicament et methode de traitement d&#39;un syndrome pathologique
WO2004012764A1 (fr) Medicament et procede de traitement des maladies de la prostate
WO2012017328A2 (fr) Composition pharmaceutique à combinaison et méthodes de traitement et de prévention des maladies infectieuses
EA029400B1 (ru) Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
JPS63502591A (ja) リユ−マチ様関節炎の治療のための方法と物質
WO2004012766A1 (fr) Procede de correction de reactions immunitaires pathologiques et preparation medicinale
US4705685A (en) Methods and materials for treatment of disease states involving immunological factors
Sagami et al. Successful use of adalimumab for treating pyoderma gangrenosum with ulcerative colitis under corticosteroid-tapering conditions
CA2473754C (fr) Traitement
WO2005039636A1 (fr) Produit pour potentialiser les effets curatifs et intensifier l&#39;action d&#39;un medicament
WO1995022336A1 (fr) Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires
WO1995016455A1 (fr) Preparation pharmaceutique a proprietes d&#39;immunosubstitution, basee sur une suspension cellulaire, et procede d&#39;utilisation de la dite preparation dans le traitement du syndrome d&#39;immunodeficience acquise (infection vih)
WO2003037372A1 (fr) Procede de retablissement de processus physiologiques perturbes et medicament
WO2003055518A1 (fr) Procede de traitement d&#39;etats immuno-pathologiques et medicament correspondant
Wilber Neuropeptides, appetite regulation, and human obesity
WO2003077946A1 (fr) Agent pharmaceutique et methode de traitement d&#39;un syndrome pathologique associe a hemodyscrasia
WO2003055517A1 (fr) Procede de correction de la reponse immunitaire et medicament
WO2004012765A1 (fr) Preparation medicinale et procede de traitement d&#39;un syndrome pathologique determine par une perturbation de l&#39;hematopoiese
RU2237484C1 (ru) Способ лечения вич-инфицированных больных
WO2001069250A1 (fr) Procede pour l&#39;immunotherapie de correction des formes precliniques et cliniques prononcees d&#39;insuffisance immunologique et procede pour la selection rapide des remede pour l&#39;immunocorrection selon guevondian
RU2500427C2 (ru) Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
RU2173171C1 (ru) Способ лечения больных клещевым энцефалитом

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载